|
1.
|
Gronowitz JS, Hagberg H, Kallander CF and
Simonsson B: The use of serum deoxythymidine kinase as a prognostic
marker, and in the monitoring of patients with non-Hodgkin’s
lymphoma. Br J Cancer. 47:487–495. 1983.
|
|
2.
|
Wu CJ, Yang RJ, Zhou J, Bao S, Zou L, Mao
YR and He Q: Production and characterisation of a novel chicken IgY
antibody raised against C-terminal peptide from human thymidine
kinase 1. J Immunol Methods. 277:157–169. 2003.
|
|
3.
|
O’Neill KL, Buckwalter MR and Murray BK:
Thymidine kinase: diagnostic and prognostic potential. Expert Rev
Mol Diagn. 1:428–433. 2001.
|
|
4.
|
Topolcan O and Holubec L Jr: The role of
thymidine kinase in cancer diseases. Expert Opin Med Diagn.
2:129–141. 2008.
|
|
5.
|
von Euler H and Eriksson S: Comparative
aspects of the proliferation marker thymidine kinase 1 in human and
canine tumour diseases. Vet Comp Oncol. 9:1–15. 2011.
|
|
6.
|
He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan
ZL, Tang LL, Hu GZ, Li Y, Zhang M, et al: Thymidine kinase 1 is a
potential marker for prognosis and monitoring the response to
treatment of patients with breast, lung, and esophageal cancer and
non-Hodgkin’s lymphoma. Nucleosides Nucleotides Nucleic Acids.
29:352–358. 2010.
|
|
7.
|
Aufderklamm S, Todenhöfer T, Gakis G,
Kruck S, Hennenlotter J, Stenzl A and Schwentner C: Thymidine
kinase and cancer monitoring. Cancer Lett. 316:6–10. 2012.
|
|
8.
|
Wu James T: Circulating Tumor Markers of
the New Millennium. AACC Press; New York: pp. 115–117. 2002
|
|
9.
|
Al-Madhoun A, Tjarks W and Eriksson S: The
role of thymidine kinases in the activation of pyrimidine
nucleoside analogues. Mini Rev Med Chem. 4:341–350. 2004.
|
|
10.
|
Jirawatnotai S, Hu Y, Michowski W, Elias
JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB,
et al: A function for cyclin D1 in DNA repair uncovered by protein
interactome analyses in human cancers. Nature. 474:230–234.
2011.
|
|
11.
|
Cigna: Markers for diagnosis and
management of cancer. USA, http://www.cigna.com.
Accessed November 15, 2011.
|
|
12.
|
Munch-Petersen B: Enzymatic regulation of
cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2:
a mini review. Nucleosides Nucleotides Nucleic Acids. 29:363–369.
2010.
|
|
13.
|
Chen YL, Eriksson S and Chang ZF:
Regulation and functional contribution of thymidine kinase 1 in
repair of DNA damage. J Biol Chem. 285:27327–27335. 2010.
|
|
14.
|
Gasparri F, Wang N, Skog S, Galvani A and
Eriksson S: Thymidine kinase 1 expression defines an activated G1
state of the cell cycle as revealed with site-specific antibodies
and ArrayScan assays. Eur J Cell Biol. 88:779–785. 2009.
|
|
15.
|
He Q, Zou L, Zhang PA, Lui JX, Skog S and
Fornander T: The clinical significance of thymidine kinase 1
measurements in serum of breast cancer patients using anti-TK1
antibody. Int J Biol Markers. 15:139–146. 2000.
|
|
16.
|
Zou L, Zhang PG, Zou S, Li Y and He Q: The
half-life of cytosolic thymidine kinase in serum by ECL dot bolt
potential marker for monitoring the response to surgery of patients
with gastric cancer. Int J Biolog Markers. 17:135–140. 2002.
|
|
17.
|
Li HX, Zhang S, Lei DS, Wang XQ, Skog S
and He Q: Serum thymidine kinase 1 is a prognostic and monitoring
factor in patients with non-small cell lung cancer. Oncol Rep.
13:145–149. 2005.
|
|
18.
|
He Q, Zhang P, Zou L, Li H, Wang X, Zhou
S, Fornander T and Skog S: Concentration of thymidine kinase 1 in
serum (S-TK1) is a more sensitive proliferation marker in human
solid tumors than its activity. Oncol Rep. 14:1013–1019. 2005.
|
|
19.
|
Zhang J, Jia Q, Zou S, Zhang P, Zhang X,
Skog S, Luo P, Zhang W and He Q: Thymidine kinase 1: A
proliferation marker for determining prognosis and monitoring the
surgical outcome of primary bladder carcinoma patients. Oncol Rep.
15:455–461. 2006.
|
|
20.
|
He Q, Fornander T, Johansson H, Johansson
U, Hu GZ, Rutqvist LE and Skog S: Thymidine kinase 1 in serum
predicts increased risk of distant or loco-regional recurrence
following surgery in patients with early breast cancer. Anticancer
Res. 26:4753–4759. 2006.
|
|
21.
|
Xu XH, Zhang YM, Shu XH, Shan LH, Wang ZW,
Zhou YL, Wen HK, He F, He E and Skog S: Serological thymidine
kinase 1 reflects progression of pre-malignant and malignant
tumours during therapy. Mol Med Rep. 1:705–712. 2008.
|
|
22.
|
Zhang GQ, Jiao SC and Wei XF: Serum
thymidine kinase 1: a proliferation marker for neoplasms in
oncologic monitoring of elderly people. J Modern Oncol. 16:831–832.
2008.(In Chinese).
|
|
23.
|
Chen ZH, Zhou H, Tian NB, et al:
Serological thymidine kinase 1 (STK1) indicates an elevated risk
for development of malignant tumours. Anticancer Res. 28:3897–3907.
2008.
|
|
24.
|
Zhang XH, Yang JR, Fu XY, Liu HX, Yun X,
Song B, Zhang M, He E and Skog S: The significance of serum
thymidine kinase 1 for the risk screening of cancer development in
pre-cancerous diseases. Chin J Health Manag. 4:35–38. 2010.
|
|
25.
|
Huang SQ, Lin J, Guo N, Zhang M, Yun X,
Liu S, Zhou J, He E and Skog S: Elevated serum thymidine kinase 1
predicts risk of pre/early cancerous progression. Asian Pac J
Cancer Prev. 12:497–505. 2011.
|
|
26.
|
Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J,
Xu XH, Chen Y, Chen QB, Wang YH, He E, Zhou J and Skog S:
Serological thymidine kinase 1 is a biomarker for early detection
of tumours - a health screening study on 35,365 people, using a
sensitive chemiluminescent dot blot assay. Sensors (Basel).
11:11064–11080. 2011.
|
|
27.
|
Chen ZH, Wang YQ, Zhu XL, Zhou H, Liu Y,
Yang PT and Cao X: Thymidine kinase 1 measurement in health check
up. Chin J Health Manag. 45:349–351. 2011.
|
|
28.
|
Yuan ZY, Liu XA, Ling LJ, Zhao Y and Wang
S: The significance of serum thymidine kinase 1 on assistant
diagnosis and evaluation of chemotherapy effect on breast cancer
patients operated. Acta Univ Med Nanjiang (Natural Science).
30:1002–1004. 2010.
|
|
29.
|
Huang H and Luo YL: The role of serum
thymidine kinase 1 levels in the postoperative evaluation of
curative effect of breast cancer. Lab Med. 26:79–81. 2011.(In
Chinese).
|
|
30.
|
Chen QB, Li CC, Zhao R, Dia Y, Chen QJ and
Chen WY: The application study on serum thymidine kinase 1 level
changes for diagnosis and therapy of breast cancers. Appl Med.
28:39–41. 2012.
|
|
31.
|
Carlsson L, Larsson A and Lindman H:
Elevated levels of thymidine kinase 1 peptide in serum from
patients with breast cancer. Ups J Med Sci. 114:116–120. 2009.
|
|
32.
|
Chen FY, Tang LL and Huang X: STK1 assay
in patients with breast cancer before and after neo-adjuvant
chemotherapy. Chin Tumor Clin. 6:732–735. 2009.
|
|
33.
|
Lu J, Chen KM, Wang ZM, Wu CY and Zhou QH:
Correlativity study on CT and serum thymidine kinase 1 of breast
diseases. Chin J CT MNR. 7:22–24. 2009.
|
|
34.
|
Zhang ZY, Chen M, Fan L and Dong RF: Serum
TK1 concentration and clinical significance in patients with
cervical carcinoma. Jilin Med. 32:7438–7439. 2012.
|
|
35.
|
Cheng XW, Yang YX, Yu XY and Liu YP:
Expression of SCC-Ag and TK1 in middle-advanced cervical carcinoma
and the significance in treatment. Chin J New Drugs. 20:1208–1300.
2011.
|
|
36.
|
Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen
D, Li X, Zhang M, Yun X, Zhou J, He E and Skog S: Serum thymidine
kinase 1 correlates to clinical stages and clinical reactions and
monitors the outcome of therapy of 1,247 cancer patients in routine
clinical settings. Int J Clin Oncol. 15:359–368. 2010.
|
|
37.
|
Li Z, Wang Y, He J, Ma J, Zhao L, Chen H,
Li N, Zhou J, He E and Skog S: Serological thymidine kinase 1 is a
prognostic factor in esophagus, cardiac and lung carcinomas. Eur J
Cancer Prev. 9:313–318. 2010.
|
|
38.
|
Guo L and Lu RQ: Significance of serum
thymidine kinase determination in patients with gastric carcinoma.
Lab Med. 23:271–273. 2008.
|
|
39.
|
Xu LB, Shen LQ and Zhuang ZX: The
expression and clinical significance of serumTK-1 in
gastrointestinal tumors. J Clin Med Prac. 17:20–23. 2011.(In
Chinese).
|
|
40.
|
Shen Z, Chen Z, Xu R, Zhang J and Jiang H:
Evaluation of the significance of serum thymidine kinase 1
detection in the diagnosis and curative effect of gastrointestinal
malignant tumors. Exp Lab Med. 5:531–533. 2011.(In Chinese).
|
|
41.
|
Jiao JH, Huan X and Shi RH: Research of
thymidine kinase1 (TK1) in diagnosis and follow-up of colorectal
carcinoma. J Clin Med Prac. 15:21–23. 2011.
|
|
42.
|
Xing H and Zhang ZF: Expression and
clinical significance of serum TK1, OPN and CEA in patients with
colorectal carcinoma. J Community Med. 9:15–18. 2011.
|
|
43.
|
Tian JG, Jia YD and Liu HT: Serum TK1,
EGF, HGF and CRP and IL-6 levels in patients with colon cancer
using laparoscopic and open surgery. Shangdong Med. 50:42–43.
2011.
|
|
44.
|
Zhang YC: Clinical significance of serum
thymidine kinase 1 with colorectal carcinomas. J Med Forum.
130:28–30. 2009.
|
|
45.
|
Wei JW, Xu CR, Zen DZ and Chen Y: Analysis
on the content of TK1 of patients with colonic polyps. Lab Med
Clin. 8:769–701. 2011.
|
|
46.
|
Li SJ, Wu G, Ye J, Zhang X, Cheng F and
Zhang KQ: The meaning of blood serum thymidine kinase level in
early screening for prostatic carcinoma. Immun J. 27:459–461.
2011.
|
|
47.
|
Luo P, He E, Eriksson S, Zhou J, Hu G,
Zhang J and Skog S: Thymidine kinase activity in serum of renal
cell carcinoma patients is a useful prognostic marker. Eur J Cancer
Prev. 18:220–224. 2009.
|
|
48.
|
Yuan H, Zhu B, Wu YW and Zhou JT: Clinical
significance of determination of changes of serum TK1 level in
patients with lung cancer. J Radioimmunol. 24:301–302. 2011.(In
Chinese).
|
|
49.
|
Zhou Y, Wang D, Yang AZ, He E, Skog S and
Zhang M: Clinical significant of detecting serum thymidine kinase1
in diagnostic and prognosis evaluation of lung cancers. Jiangshu
Med. 38:310–313. 2012.
|
|
50.
|
Guan Y, Guo QS, Shan FL and Liu IJ:
Expression and significance of thymidine kinase 1 in small cell
lung carcinoma tissues. Chin J Cancer Prev Treat. 17:746–748.
2010.
|
|
51.
|
Feng MH: The significance of the detection
of serum thymidine kinase in treatment assessment of lung
carcinomas. J Radioimmunol. 24:455–456. 2011.
|
|
52.
|
Xu W, Shen QD and Yu H: Serum thymidine
kinase and LPL and its associated prognostic factors in chronic
lymphocytic leukemia. Chin J Hematol. 30:23–26. 2009.
|
|
53.
|
Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu
Q, Fan L and Li JY: Serum thymidine kinase 1 concentration in
Chinese patients with chronic lymphocytic leukemia and its
correlation with other prognostic factors. Int J Hematol.
90:205–211. 2009.
|
|
54.
|
Zeng ZJ, Uyang WT, Sun YH and Cai XH:
Clinical significance of thymidine kinase 1 in chemotherapy of
leukemia. J Mol Diagn Ther. 1:28–31. 2009.
|
|
55.
|
Pan ZL, Ji XY, Shi YM, Zhou J, He E and
Skog S: Serum thymidine kinase 1 concentration as a prognostic
factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J
Cancer Res Clin Oncol. 136:1193–1199. 2010.
|
|
56.
|
Chen QB, Liu RP, Huang H, Li Q, Zhang JY,
Zhen SB, Li Q, Jing N and Zhen L: Serum thymidine kinase 1 and its
role in monitoring and prognosis of tumor. Guangdong Med.
29:1022–1024. 2008.
|
|
57.
|
Li QR, Yuan H, Sang SB, Su CH, Wu YW,
Zhang M, Zhou J, Zhao JT, He E and Skog S: The significance of
serum thymidine kinase 1 for early tumor detection and monitoring
the response to therapy. Chin J Nuclear Med. 29:271–273. 2009.
|
|
58.
|
Wang LJ: Clinical significance of
cytoplasmic thymidine kinase in patients with malignant tumors.
Heilongjiang Med. 24:904–905. 2011.
|
|
59.
|
Wang ZX, Zhang B, Ni B and Zhan J: Value
of serum thymidine kinase 1 in evaluating the efficacy of malignant
tumor treatment. Jiangsu Med J. 18:2174–2175. 2011.(In
Chinese).
|
|
60.
|
Mao RY, Wu JP, Wang N, He LX, Wu CJ, He Q
and Skog S: A comparison study: immunohistochemical detection of
cytosolic thymidine kinase and proliferating cell nuclear antigen
in breast cancer. Cancer Invest. 20:922–931. 2002.
|
|
61.
|
Wu JP, Mao YR, He LX, Wang N, Wu CJ, He Q
and Skog S: Comparison study on the expression of cytosolic
thymidine kinase and proliferating cell nuclear antigen in
colorectal carcinoma. Anticancer Res. 20:4815–4820. 2000.
|
|
62.
|
He Q, Mao Y, Wu J, Decker C, Merza M, Wang
N, Eriksson S, Castro J and Skog S: Cytosolic thymidine kinase is a
specific histopathologic tumour marker for breast carcinomas. Int J
Oncol. 25:945–953. 2004.
|
|
63.
|
Mao YR, Wu JP, Skog S, Eriksson S, Zhao Y,
Zhou J and He Q: Expression of cell proliferating genes in patients
with non-small-cell lung cancer (NSCLC) by immunohistochemistry and
cDNA profiling. Oncol Rep. 13:837–846. 2005.
|
|
64.
|
Guan H, He E, Zhou J, Li Y, Eriksson S and
Skog S: Thymidine kinase 1 expression is significantly different in
breast benign (UDH), and in pre-malignant (ADH), primary tumour
in situ (DCIS) and invasive ductal (IDC) of breast
carcinoma. Mol Med Rep. 2:923–929. 2009.
|
|
65.
|
Liu C, Gao Q, Shi QL, Yu B, Ma HH,
Eriksson S, He E and Skog S: Significance of TK1 and Ki-67
expression in ovarian serous adenocarcinoma. J Clin Exp Pathol.
27:1289–1293. 2011.
|
|
66.
|
Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B,
Zhou X, Eriksson S, He E and Skog S: High thymidine kinase 1 (TK1)
expression is a predictor of poor survival in patients with pT1 of
lung adenocarcinoma. Tumour Biol. 33:475–483. 2012.
|
|
67.
|
Luo P, Wang N, He E, Eriksson S, Zhou J,
Hu G, Zhang J and Skog S: The proliferation marker thymidine kinase
1 level is high in normal kidney tubule cells compared to other
normal and malignant renal cells. Pathol Oncol Res. 16:277–283.
2010.
|
|
68.
|
Gakis G, Hennenlotter J, Scharpf M, Hevler
J, Schilling D, Kuehs U, Stenzl A and Schwentner C: XPA-210: a new
proliferation marker to characterize tumor biology and progression
of renal cell carcinoma. World J Urol. 29:801–806. 2011.
|
|
69.
|
Ye FP, Xie QL, Liu XL, Zhen JH, Lan JL and
Yu M: Expression of TK1 and Ki67 in prostate diseases. J Clin Exp
Pathol. 24:644–667. 2008.
|
|
70.
|
Aufderklamm S, Hennenlotter J, Todenhoefer
T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J,
Merseburger A, et al: XPA-210: a new proliferation marker
determines locally advanced prostate cancer and is a predictor of
biochemical recurrence. World J Urol. Oct 4–2011, (Epub ahead of
print).
|
|
71.
|
Yang L, Parkin DM, Ferlay J, Li L and Chen
Y: Estimates of cancer incidence in China for 2000 and projections
for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250. 2005.
|
|
72.
|
Barregard L, Holmberg E and Sallsten G:
Leukaemia incidence in individualsliving close to an oil refinery.
Environ Res. 109:985–990. 2009.
|
|
73.
|
Berman JJ and Moor GW: Precancer: The
Beginning and the End of Cancer. Jones and Bartlett Learning Inc.;
Boston: 2010
|
|
74.
|
Nisman B, Allweis T, Kaduri L, Maly B,
Gronowitz S, Hamburger T and Peretz T: Serum thymidine kinase 1
activity in breast cancer. Cancer Biomark. 7:65–72. 2010.
|
|
75.
|
Kemik O, Kemik AS, Purisa S and Tuzun S:
Serum thymidine kinase is associated with gastric adenocarcinoma.
Bratisl Lek Listy. 112:510–511. 2011.
|
|
76.
|
Letocha H, Eklov S, Gronowitz S, Johan BN
and Nilsson S: Deoxythymidine kinase in the staging of prostatic
adenocarcinoma. Prostate. 29:15–19. 1996.
|
|
77.
|
Nisman B, Yutkin V, Nechushtan H, Gofrit
ON, Peretz T, Gronowitz S and Pode D: Circulating tumor M2 pyruvate
kinase and thymidine kinase 1 are potential predictors for disease
recurrence in renal cell carcinoma after nephrectomy. Urology.
76:513–516. 2010.
|
|
78.
|
Konoplev SN, Fritsche HA, O’Brien S,
Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K,
Johnson MR, et al: High serum thymidine kinase 1 level predicts
poorer survival in patients with chronic lymphocytic leukemia. Am J
Clin Pathol. 134:472–477. 2010.
|
|
79.
|
Procházka V, Faber E, Raida L, Langová K,
Indrák K and Papajík T: High baseline serumthymidine kinase 1 level
predicts unfavorable outcome in patients with follicular lymphoma.
Leuk Lymphoma. 53:1306–1310. 2012.
|
